Medical News / From AAO 2021 - David R. Lally, MD: Analyzing Nascent GA, Intermediate AMD Progression from GATHER1

Over the weekend, important data on avacincaptad pegol treatment in patients from the GATHER1 clinical trial with nascent geographic atrophy and intermediate age-related macular degeneration (AMD) progression was presented at the American Academy of Ophthalmology 2021 Meeting. In an interview with HCPLive, presenting author, David R. Lally, MD, Assistant Professor of Surgery, University of Massachusetts Medical School - Baystate, highlighted the key takeaways of the analysis. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

According to new phase 3 data presented at the American Academy of Ophthalmology 2021 Meeting, brolucizumab ... read more
In an interview with HCPLive, Veeral Sheth, MD, Director of Clinical Trials, University Retina, discussed the ... read more
Access to US ophthalmology clinical trial sites may differ by region, according to new study findings ... read more
Although there are questions on the rationale behind step therapy, particularly for neovascular (wet) age-related macular ... read more